THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Clinical trials for THERAPY-RELATED MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for THERAPY-RELATED MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug cocktail shows promise for tough blood cancers, but study halted early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 00:44 UTC
-
Promising combo for tough blood cancer hits snag, study stopped early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, for people with a high-risk type of bone marrow cancer called myelodysplastic syndrome (MDS) that either came back or didn't respond to treatment. The goal was to find the best dose and see how well it work…
Matched conditions: THERAPY-RELATED MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC